Sarkosyl disrupted the complex and rendered PrPc sensitive to protease digestion. While the pathogenic All TV mutation increased the efficacy of complex formation, anti-PrP mono clonal antibody prevented interaction between PrPc and pep tides. Our findings in concert with transgenetic investigations argue that PrPc interacts with PrPSc through a domain that contains the first two putative a-helices. Whether PrPc-peptide complexes possess prion infectivity as determined by bioassays remains to be established.
Although many lines of evidence have converged to argue persuasively that prions are composed of the scrapie isoform of prion protein (PrPSc) (1) , identifying conditions for the in vitro conversion of the cellular isoform (PrPc) into PrPSc wherein scrapie infectivity is generated de novo remains to be accomplished. Formation of PrPSc is a posttranslational pro cess (2) in which PrPc forms a complexwith PrPSc and is then transformed into a second molecule of PrPSc (3) . While attempts to detect a covalent change that distinguishes PrPc from PrPSc were unsuccessful (4), spectroscopic studies dem onstrated that PrPc contains -40% cv-helix and is devoid of 0-sheet (5) . In contrast, PrPSc has a high 0-sheet content, which correlates with scrapie infectivity (6) (7) (8) (9) .
Once studies of mice expressing Syrian hamster (SHa) PrP transgenes indicated that PrPc and PrPSc form a complex during the formation of nascent PrPSc (3), we attempted to demonstrate PrPSc production through formation of such complexes by mixing purified fractions containing equimolar amounts of the two isoforms (10) . Unable to demonstrate conversion of PrPc into PrPSc in these mixtures, we pursued the interactions of synthetic PrP peptides that correspond to regions of putative secondary structure and display confor mational pluralism (11, 12) . In contrast to our earlier findings, other investigators were able to demonstrate an interaction
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between PrPSc and PrPc by mixing a 50-fold excess of PrPSc with labeled PrPc (13).
In the current study, PrP peptides encompassing the first two putative a-helical regions and mimicking many structural features of the two PrP isoforms (14, 15) were mixedwith PrPc, which became resistant to proteolytic digestion and sedi mented at 100,000 X g for 1 h. Mixtures of PrPc and peptides formed fibrous aggregates and displayed a high /3-sheet con tent. Addition of 2% Sarkosyl disrupted the PrPc-peptide complex and rendered PrPc sensitive to protease digestion;
anti-PrP monoclonal antibody (mAb) prevented complex for mation. Unexpectedly, the peptide in a 0-sheet conformation did not bind PrPc, whereas the random coil did. When the pathogenic A117V mutation causing both the telencephalic and ataxic forms of Gerstmann-Straussler-Scheinker disease (16) (17) (18) was substituted in the peptide, =65% of the radiola beled PrPc formed sedimentable complexes. Our findings in concert with transgenetic investigations argue that PrPc inter acts with PrPSc through a domain that contains the first two putative a-helices.
MATERIALS AND METHODS
SHaPrP was subcloned into the glutamine synthetase expres sion vector pEE 12 (Cell/Tech, Alameda, CA). Chinese hamster ovary (CHO) Kl cells (American Type Culture Col lection) were seeded at 106 cells per 10-cm dish in GMEM-S medium containing 10% dialyzed fetal calf serum (GIBCO/ BRL) (19) . Cells were transfected with 10 /ig of pEE 12-SHaPrP vector per dish by the CaP04 method (20) . After growing cells in 25 /u,M methionine sulfoximine (MSX) (Sig ma) for 2 weeks, 60 clones were selected and grown in 100,200, or 400 jjM MSX. The clones were analyzed by Western blotting to identify the highest expressors (21) . From clone 30C1, phosphatidylinositol-specific phospholipase C digestion re leased -90 ng of SHaPrPc from 106 cells (22) . The CHO cells expressing SHaPrPc were metabolically radiolabeled with [35S]methionine (100 jxCi/ml; 1 Ci = 37 GBq; NEN) (2) and immunoaffinity purified (23) from cell lysates by using the anti-PrP 3F4 mAb (24) , which recognizes SHaPrP residues 109-112 (25) . SHaPrPc was eluted from mAb/protein A-Sepharose with 3 M guanidine hydrochloride (Gdn-HCl) and centrifuged at 16,000 X g for 2 min at 4°C, and (26) and sacrificed when they showed signs of central nervous system dysfunction. SHaPrPSc was purified from the brains of these ill animals (27) . Similarly, mouse (Mo) PrPSc was purified from the brains of ill mice inoculated with RML prions (28) .
SHaPrPc was purified from the brains of uninoculated adult SHa (5) and radioiodinated with 125I (1 mCi per 100 /u,g of PrPc; Amersham) using Iodo-Beads (Pierce) (29) .
PrP peptides were synthesized and purified as described; conformations were established by Fourier transform infrared spectroscopy and CD (12, 14) . Proteinase K (GIBCO/BRL) was used at a concentration of 50 ju-g/ml and incubated for 1 h at 37°C. Although PrPsc was digested in 3 M Gdn-HCl, in some cases the activity of proteinase K was reduced =90%, as measured by a colorimetric assay with carbobenzoxyvalylglycylarginine pnitroanilide (Boehringer Mannheim). Digestions with proteinase K were terminated by addition of 1 mM (4-amidinophenyl) methanesulfonyl fluoride (Boehringer Mannheim). SDS/PAGE was performed according to Laemmli (30) and autoradiograms were obtained. Immunoblots were performed using the ECL system (Amersham) with anti-PrP 3F4 mAb. Using a JEOL 100CX electron microscope, samples were viewed at 80 keV after negative staining.
Fifty nanograms of 35S-SHaPrPc at a concentration =10 ju,g/mlwas incubated in Eppendorf microcentrifuge tubes with TN buffer for up to 48 h at 37°C. PrP peptides were mixed with immunopurified, radiolabeled PrPc in 0.3 M Gdn-HCl at molar ratios ranging from 50:1 to 5000:1. Anti-PrP 3F4 and 13A5 mAbs (31) were added to SHaPrPc in molar ratios of 500:1 or 1000:1. SHa-or MoPrPSc was incubated with SHaPrPc in mo lar ratios ranging from 1:1 to 50:1. The PrPSc (=1 mg/ml) was pretreated with Gdn-HCl at concentrations ranging from 0 to 6 M for 16 h at 37°C. Upon termination of the incubation, an equal volume of TN buffer was added to all samples and analyses were performed immediately.
RESULTS

PrP Peptides Promote Formation of Protease-Resistant
PrP. Having found that small PrP peptides can interact and induce conformational changes (12) and that a 56-residue peptide denoted SHa 90-145, which corresponds to the N terminus of PrP 27-30, displayed multiple conformations (14), we asked if synthetic peptides mixed with PrPc could alter its properties. When the random coil peptide was incubated with 35S-PrPc at a ratio of 5000:1, it induced protease resistance ( Fig. \A, lanes 1-4) . The same peptide in the j8-sheet form did not produce resistance to proteolysis (lanes 5-7). When Mo 90-145 in either the random coil or /3-sheet form was mixed with SHaPrPc, it did not induce a change in protease resistance (lanes 8 and 9) .
To localize the region in which PrP peptides interact with PrPc, we examined shorter peptides. Neither HI containing residues 109-122 nor a longer version denoted 104H1 com posed of residues 104-122 could produce protease resistance in PrPc after mixing ( 
Properties of PrPc-Peptide Complexes.
Since the protease resistance of the PrPc-peptide complexes resembled that of PrPSc, we asked if, like PrPSc, the complexeswere insoluble (27, 32, 33) . 35S-PrPc was incubated with or without SHa 90-145 (A117V) followed by centrifugation at 100,000 x g. Without peptide, <10% of the 35S-PrPc was sedimented, whereas addition of SHa 90-145 (A117V) resulted in =65% of the radiolabel in the pellet. Fourier transform infrared spectros copy of the sedimented PrPc-SHa 90-145 complex showed a substantial increase in /3-sheet content compared to pelleted PrPc ( Fig. 2A) . As measured by CD, the supernatant contain ing primarily unbound SHa 90-145 peptide remained random coil, as did the peptide incubated alone in TN buffer for 48 h (data not shown). It is unknown how much of the increase in /3-sheet content was contributed by PrPc and how much was contributed by the peptide. Treating PrPc with 50% acetonitrile for 48 h at 37°C did not produce protease-resistant PrPc. When incubated without peptide, PrPc pellets showed many spherical aggregates up to 20 nm in diameter (Fig. 25) . In contrast, numerous large, filamentous polymers were found in the pellets of the PrPc-peptide mixture (Fig. 2C) .
Anti-PrP mAb Binding to PrPc. Since both anti-PrP 3F4 and 13A5mAbs bind to SHaPrPc within the region spanned by the SHa 90-145 peptide, we asked if these mAbs could prevent acquisition of protease resistance. Both mAbs prevented for mation of protease-resistant PrPc-peptide complexes (Fig. 3A,   lanes 3 and 4) .
Spontaneous Formation of Protease-Resistant PrP.
We next asked if PrPc incubated in the absence of PrP peptides could become protease resistant. Immunopurified PrPc (10 /xg/ml) from CHO cells (Fig. 3B, lanes 1-4) Approximately 1% of the PrPc was found to be protease resistant after 48 h under these conditions (Fig. 32? )compared to =50% of the PrPc that was rendered protease resistant with the SHa 90-145 (A117V) peptide (Fig. 1) . PrPc overexpressed in CHO exhibited a broad size range presumably due to hyperglycosylation (Fig. 3B, lane 1 3 M Gdn-HCl undergoes renaturation and renders PrPc resistant to proteolysis within 2 min of mixing (13) . Since numerous attempts to renature prion infectivity from both Gdn and urea had failed (34), we investigated the effect of 3 M Gdn-HCl on PrPSc. As before, we were unable to demon strate renaturation of PrPSc that had been denatured in 3 M Gdn-HCl and then diluted 1:4 to 1:10 before limited protease digestion and SDS/PAGE (Fig. 4A) . Of note, when the dilution was carried out in the same tube to which the 3 M Gdn-HCl had been added, we did see protease-resistant PrP (data not shown). This was never seen when the tubes were changed, and we surmise that this was due to residual, unde natured PrPSc bound to the walls of the tube.
When we mixed PrPSc that had been denatured in 3 M Gdn-HCl and then diluted in buffer to give a final concentra tion of 0.3-2 M Gdn-HCl with PrPc, no protease-resistant 35S-PrPc could be detected. However, mixing undenatured prpsc wjtn prpc djjj prociUce protease-resistant 35S-PrPc (Fig.   3A, lane 6) . As reported by others (13), a 50-fold excess of prpsc was required to produce protease-resistant 35S-PrPc, while a 1:10 excess of PrPSc did not. The presence of 0.3 M Gdn-HCl in the reaction mixture seems to be essential since its removal by methanol precipitation before mixing prevented complex formation. Although =50% of the 35S-PrPc was recovered in complexes sedimented at 100,000 x gfor 1 h, only 10-15% was protease resistant.
Anti-PrP mAb Prevents Binding of PrPSc to PrPc. The interaction between PrPc and PrPSc was found to be inhibited
by the anti-PrP 3F4 but not 13A5 mAb (Fig. 14, lanes 7 and  8) . This difference between the two mAbs might indicate a critical role for the PrP residues in the vicinity of the 3F4 epitope, which is at the N terminus of the HI region, or reflect a difference in the avidity of the two mAbs. PrPc-II truncated at the N terminus and lacking the 3F4 epitope did not exhibit protease resistance after exposure to PrPSc (data not shown), supporting the notion that the HI region, in which the 3F4 epitope lies, is particularly significant (23, 35) .
We estimate that 15-20% of PrPc mixed with PrPSc acquired protease resistance after 48 h in contrast to mixing with the SHa 90-145 (A117V) peptide where «50% PrPc demon strated protease resistance.After incubationwith SHa 90-145 for 1 h, «35% of the 35S-PrPc that exhibited protease resis tance at 48 h was present; by 24 h,^75% of the PrPc was protease resistant. Although it has been reported that protease-resistant 35S-PrPc was generated within 2 min after mixing with a 50-fold excess of unlabeled PrPSc, we were unable to reproduce this finding (13) .
Species Specificity of PrPSc Binding to PrPc. When we mixed MoPrPSc with SHaPrPc, relatively little proteaseresistant PrPc was formed (Fig. AB, lanes 1 and 2) and addition of Sarkosyl rendered the complex sensitive to proteolysis (lanes [3] [4] [5] . In contrast, the 35S-PrPc-SHaPrPSc complex was resistant to proteolysis (lanes 6-10), even when exposed to up to 2% Sarkosyl for 48 h before digestion. These results are consistent with the finding that SHa 90-145 mixed with SHaPrPc produced protease-resistant protein, whereas Mo 90-145 mixed with SHaPrPc did not (Fig. 1 ). PrPc is equivalent to PrPSc (13) . Interestingly, the binding of PrPc to PrPScwas found to be dependent on the same residues (41) that render transgenic MH2M mice susceptible to SHa prions (39) and it seems to be strain dependent (42) .Although we were able to confirm the binding of PrPc to PrPSc in the presence of a large excess of PrPSc (Fig. 3A and AB) , we were unable to reproduce the renaturation of PrPSc from Gdn-HCl as judged by a restoration of protease resistance (Fig. AA) .
Attempts found in transgenic SHaPrP mice inoculated with SHa prions, none were detected in the mice inoculated with Mo prions (3). Thus, amyloid deposition in plaque formation is not obligatory for prion propagation. Ultrastructural studies demonstrated that purified PrPSc molecules exist as amorphous aggregates, which, when partially digested with proteinase K in the pres ence of detergent, form PrP 27-30 that polymerizes into rod-shaped particles with the properties of amyloid (5, 33) .
The SHa 90-145 peptide adopts an a-helical structure in hydrophobic environments created by detergents or lipids while it displays a random coil in H20 (14) . Although 2-3 weeks was required for SHa 90-145 in the presence of 150 mM NaCl to acquire j3-sheet conformation and resistance to pro teolysis, it displayed these features after 48 h upon mixing with PrPc. While these physical properties of SHa 90-145 resemble those of PrPSc, this peptide injected intracerebrally into ro dents has not produced central nervous system dysfunction to date.
Our investigations offer an additional approach to the study of prions. Synthetic PrP peptides can be used to map regions where PrP molecules interact with each other and to define the degree of homology that facilitates binding. It is likely that this knowledge can be translated to direct the construction of PrP transgenes with predetermined specificities. Since the PrP peptides used in our studies have not exhibited prion infec tivity, it will be possible to determine whether the PrPcpeptidecomplexes that mimic manyof the featuresof PrPSc are capable of transmitting prion disease in inoculated animals.
